Need professional-grade analysis? Visit stockanalysis.com
$33.69M
N/A
N/A
N/A
Lixte Biotechnology Holdings Inc (LIXT) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $3.98, up 3.92% from the previous close.
Over the past year, LIXT has traded between a low of $0.71 and a high of $6.00. The stock has gained 210.9% over this period. It is currently 33.7% below its 52-week high.
Lixte Biotechnology Holdings Inc has a market capitalization of $33.69M.
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Side-by-side comparison against top Healthcare peers.